Product Description
BLZ945, a highly selective brain penetrant CSF-1R kinase inhibitor, is being explored as single agent and with the anti-PD-1 mAb, spartalizumab. (Sourced from: https://aacrjournals.org/cancerres/article/80/16_Supplement/CT171/645264/Abstract-CT171-Phase-I-study-of-BLZ945-alone-and)
Mechanisms of Action: CSF1R Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis|Oncology Solid Tumor Unspecified
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031230272 | P1 |
Recruiting |
Healthy Volunteers |
2024-06-30 |
|
| 2019-000826-22 | P2 |
Active, not recruiting |
Amyotrophic Lateral Sclerosis |
2024-01-16 |
|
| JapicCTI-183903 | P2 |
Active |
Oncology Solid Tumor Unspecified |
2021-06-30 |
|
| 2015-005806-12 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2019-05-28 |